Skip to main content
Year archive

MorphoSys AG — 2018 filings

All 98 regulatory filings released by MorphoSys AG (MOR) in 2018, sourced directly from the official regulator.

98 Filings
2018 Period
2018 filings (98)
Filing Released Lang
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-12-18 English
Report Publication Announcement 2018
Report Publication Announcement
2018-12-17 English
MorphoSys AG: Corporate Calendar 2019 (news with additional features)
Report Publication Announcement
2018-12-17 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-12-13 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-12-06 English
MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018 (news with additional features)
Regulatory Filings
2018-12-02 English
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis (news with additional features)
Regulatory Filings
2018-11-26 English
MorphoSys to Present at Upcoming Investor Conferences
Regulatory Filings
2018-11-21 English
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa (news with additional features)
Legal Proceedings Report
2018-11-19 English
MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210 (news with additional features)
Regulatory Filings
2018-11-15 English
Q3 statement / Q3 financial report 2018
Interim / Quarterly Report 9M 2018
2018-11-08 German
MorphoSys AG Announces Third Quarter 2018 Results (news with additional features)
Interim / Quarterly Report Q3 2018
2018-11-05 English
MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting (news with additional features)
Regulatory Filings
2018-11-01 English
MorphoSys to Host Q3 2018 Conference Call on November 6, 2018 (news with additional features)
Earnings Release Q3 2018
2018-10-29 English
MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference (news with additional features)
Regulatory Filings
2018-10-21 English
MorphoSys to Present at Upcoming Investor Conferences (news with additional features)
Regulatory Filings
2018-09-27 English
MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients (news with additional features)
Regulatory Filings
2018-09-25 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-09-25 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-09-21 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-09-21 English
MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics (news with additional features)
Regulatory Filings
2018-09-17 English
MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106 (news with additional features)
Regulatory Filings
2018-09-13 English
MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner (news with additional features)
Legal Proceedings Report
2018-09-12 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-09-06 English
MorphoSys AG to be listed in MDAX (news with additional features)
Regulatory Filings
2018-09-06 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2018-08-31 English
MorphoSys to Present at Upcoming Investor Conferences (news with additional features)
Report Publication Announcement
2018-08-21 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-08-09 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-08-08 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-08-08 English
MorphoSys and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202 (news with additional features)
Regulatory Filings
2018-08-08 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-08-07 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-08-07 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-08-07 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-08-07 English
Half-yearly financial report 2018
Interim / Quarterly Report H2 2018
2018-08-02 German
MorphoSys AG Reports Second Quarter 2018 Financial Results (news with additional features)
Earnings Release Q2 2018
2018-08-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2018-07-31 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-07-25 English
MorphoSys to Host Q2 2018 Conference Call on August 2, 2018
Report Publication Announcement
2018-07-25 English
MorphoSys Announces Appointment of Jennifer Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial (news with additional features)
Board/Management Information
2018-07-24 English
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Pharma Partner (news with additional features)
M&A Activity
2018-07-19 English
Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018
Regulatory Filings
2018-07-19 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-07-17 English
MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn's Disease (news with additional features)
Regulatory Filings
2018-07-10 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-07-04 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-06-21 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-06-19 English
MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference (news with additional features)
Regulatory Filings
2018-06-15 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-06-13 English
New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in Early Alzheimer's Disease now Underway (news with additional features)
Regulatory Filings
2018-06-12 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-06-11 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-06-08 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-06-08 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-06-08 English
MorphoSys to Present at Upcoming Investor Conferences
Report Publication Announcement
2018-06-04 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-05-30 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-05-25 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-05-18 English
MorphoSys to Present at Upcoming Investor Conferences (news with additional features)
Report Publication Announcement
2018-05-18 English
Annual General Meeting of MorphoSys AG Elects New Supervisory Board Members (news with additional features)
AGM Information
2018-05-17 English
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 Conference (news with additional features)
Legal Proceedings Report
2018-05-17 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-05-14 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-05-04 English
Q1 statement / Q1 financial report 2018
Interim / Quarterly Report Q1 2018
2018-05-03 German
MorphoSys AG Reports First Quarter 2018 Results (news with additional features)
Earnings Release Q1 2018
2018-05-02 English
MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial With MOR106 in Atopic Dermatitis Patients (news with additional features)
Regulatory Filings
2018-05-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2018-04-30 English
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea (news with additional features)
Regulatory Filings
2018-04-26 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-04-26 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-04-26 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2018-04-26 English
MorphoSys to Host Q1 2018 Conference Call on May 3, 2018
Report Publication Announcement
2018-04-25 English
MorphoSys AG: Updated Corporate Calendar 2018
Report Publication Announcement
2018-04-25 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-04-24 English
Report Publication Announcement 2018
Report Publication Announcement
2018-04-24 English
Report Publication Announcement 2018
Report Publication Announcement
2018-04-24 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2018-04-23 English
MorphoSys Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq (news with additional features)
Capital/Financing Update
2018-04-18 English
MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
Capital/Financing Update
2018-04-18 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-04-11 English
DGAP-DD: MorphoSys AG english
Director's Dealing
2018-04-11 English
MorphoSys Nominates New Candidates for Supervisory Board (news with additional features)
Board/Management Information
2018-04-10 English
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 17.05.2018 in Munchen mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2018-04-10 German
Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States
Capital/Financing Update
2018-04-09 English
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) for the Treatment of Moderate to Severe Forms of Psoriasis and Psoriatic Arthritis in Japan (news with additional features)
Regulatory Filings
2018-04-06 English
MorphoSys Announces Approvals for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Brazil and Australia (news with additional features)
Regulatory Filings
2018-04-05 English
Annual financial report 2017
Annual Report FY 2017
2018-03-28 English
Jahresfinanzbericht 2017
Annual Report FY 2017
2018-03-28 German
Ad hoc: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering
Capital/Financing Update
2018-03-22 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-03-21 English
Clinical Data Presentations at AAT in Alzheimer's Disease (news with additional features)
Regulatory Filings
2018-03-14 English
MorphoSys Reports Updated Data from L-MIND Study of MOR208 plus Lenalidomide in Aggressive Lymphoma (r/r DLBCL) (news with additional features)
Legal Proceedings Report
2018-03-13 English
MorphoSys Presents Results for Fiscal Year 2017 (news with additional features)
Earnings Release FY 2017
2018-03-13 English
Invitation to Year-End Results 2017 Conference Call
Report Publication Announcement
2018-03-08 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-03-06 English
Invitation to Year-End Results 2017 Conference Call
Report Publication Announcement
2018-03-01 English
MorphoSys Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-Term Skin Clearance In Patients With Moderate-To-Severe Plaque Psoriasis (news with additional features)
Regulatory Filings
2018-02-20 English